These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 10831533)

  • 21. Efficacy and safety of a new selective class III antiarrhythmic agent dofetilide in paroxysmal atrial fibrillation or atrial flutter.
    Suttorp MJ; Polak PE; van 't Hof A; Rasmussen HS; Dunselman PH; Kingma JH
    Am J Cardiol; 1992 Feb; 69(4):417-9. PubMed ID: 1734660
    [No Abstract]   [Full Text] [Related]  

  • 22. Clinical efficacy of dofetilide for the treatment of atrial tachyarrhythmias in adults with congenital heart disease.
    Banchs JE; Baquero GA; Nickolaus MJ; Wolbrette DL; Kelleman JJ; Samii S; Grando-Ting J; Penny-Peterson E; Davidson WR; Young SK; Naccarelli GV; Gonzalez MD
    Congenit Heart Dis; 2014; 9(3):221-7. PubMed ID: 23947935
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dofetilide (Tikosyn): a new drug to control atrial fibrillation.
    Saliba WI
    Cleve Clin J Med; 2001 Apr; 68(4):353-63. PubMed ID: 11326815
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemical cardioversion of atrial fibrillation with intravenous dofetilide.
    Sedgwick ML; Lip G; Rae AP; Cobbe SM
    Int J Cardiol; 1995 Apr; 49(2):159-66. PubMed ID: 7628887
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dofetilide: a new pure class III antiarrhythmic agent.
    Falk RH; Decara JM
    Am Heart J; 2000 Nov; 140(5):697-706. PubMed ID: 11054613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [New antiarrhythmic agents in atrial fibrillation].
    Hernández GP; Ortíz PL; López FA; Mondragón Ldel V
    Arch Cardiol Mex; 2007; 77 Suppl 2():S2-59-S2-63. PubMed ID: 17972381
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dofetilide (Tikosyn).
    Song JC; White CM
    Conn Med; 2000 Oct; 64(10):601-4. PubMed ID: 11100632
    [No Abstract]   [Full Text] [Related]  

  • 28. Pericardioversion dofetilide does not suppress immediate and subacute recurrences of persistent atrial fibrillation.
    Van Noord T; Van Gelder IC; Crijns HJ
    Circulation; 2001 Sep; 104(11):E57. PubMed ID: 11551891
    [No Abstract]   [Full Text] [Related]  

  • 29. Dofetilide and atrial fibrillation.
    Benson LM; Powless D
    Am J Nurs; 2003 Feb; 103(2):64AA-64CC, 64EE-64GG. PubMed ID: 12582342
    [No Abstract]   [Full Text] [Related]  

  • 30. Positive atrial inotropic effect of dofetilide after cardioversion of atrial fibrillation or flutter.
    DeCara JM; Pollak A; Dubrey S; Falk RH
    Am J Cardiol; 2000 Sep; 86(6):685-8, A8. PubMed ID: 10980226
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute conversion of persistent atrial fibrillation during dofetilide initiation.
    Cotiga D; Arshad A; Aziz E; Joshi S; Koneru JN; Steinberg JS
    Pacing Clin Electrophysiol; 2007 Dec; 30(12):1527-30. PubMed ID: 18070309
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dofetilide: is the treatment worse than the disease?
    Lauer MR
    J Am Coll Cardiol; 2001 Mar; 37(4):1106-10. PubMed ID: 11263616
    [No Abstract]   [Full Text] [Related]  

  • 33. Dofetilide--medical and media information.
    S Afr Med J; 1996 Apr; 86 Suppl 2():C112-3. PubMed ID: 8711572
    [No Abstract]   [Full Text] [Related]  

  • 34. Does conversion and prevention of atrial fibrillation enhance survival in patients with left ventricular dysfunction? Evidence from the Danish Investigations of Arrhythmia and Mortality ON Dofetilide/(DIAMOND) study.
    Pedersen OD; Brendorp B; Elming H; Pehrson S; Køber L; Torp-Pedersen C
    Card Electrophysiol Rev; 2003 Sep; 7(3):220-4. PubMed ID: 14739717
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dofetilide, a novel class III antiarrhythmic agent.
    Rasmussen HS; Allen MJ; Blackburn KJ; Butrous GS; Dalrymple HW
    J Cardiovasc Pharmacol; 1992; 20 Suppl 2():S96-105. PubMed ID: 1279316
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study.
    Singh S; Zoble RG; Yellen L; Brodsky MA; Feld GK; Berk M; Billing CB
    Circulation; 2000 Nov; 102(19):2385-90. PubMed ID: 11067793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of the novel antiarrhythmic agent azimilide on experimental atrial fibrillation and atrial electrophysiologic properties.
    Nattel S; Liu L; St-Georges D
    Cardiovasc Res; 1998 Mar; 37(3):627-35. PubMed ID: 9659446
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of heart failure.
    Le Jemtel TH
    Curr Cardiol Rep; 2000 May; 2(3):221-4. PubMed ID: 10980896
    [No Abstract]   [Full Text] [Related]  

  • 39. QTC intervals can be assessed with the AliveCor heart monitor in patients on dofetilide for atrial fibrillation.
    Chung EH; Guise KD
    J Electrocardiol; 2015; 48(1):8-9. PubMed ID: 25453194
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence, prognostic significance, and treatment of atrial fibrillation in congestive heart failure with particular reference to the DIAMOND-CHF study.
    Pedersen OD; Brendorp B; Køber L; Torp-Pedersen C
    Congest Heart Fail; 2003; 9(6):333-40. PubMed ID: 14688506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.